MX2021010916A - Inhibidores rad51. - Google Patents
Inhibidores rad51.Info
- Publication number
- MX2021010916A MX2021010916A MX2021010916A MX2021010916A MX2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A
- Authority
- MX
- Mexico
- Prior art keywords
- rad51
- inhibitors
- rad51 inhibitors
- directed
- represented
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001195 RAD51 Human genes 0.000 abstract 1
- 108010068097 Rad51 Recombinase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816998P | 2019-03-12 | 2019-03-12 | |
| PCT/US2020/022293 WO2020186006A1 (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010916A true MX2021010916A (es) | 2021-10-01 |
Family
ID=72422797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010916A MX2021010916A (es) | 2019-03-12 | 2020-03-12 | Inhibidores rad51. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11247988B2 (https=) |
| EP (1) | EP3938358B1 (https=) |
| JP (1) | JP7460649B2 (https=) |
| KR (1) | KR20210127790A (https=) |
| CN (1) | CN114072390B (https=) |
| AU (1) | AU2020235089A1 (https=) |
| BR (1) | BR112021017336A2 (https=) |
| CA (1) | CA3132987A1 (https=) |
| IL (1) | IL285889B2 (https=) |
| MX (1) | MX2021010916A (https=) |
| PH (1) | PH12021552147A1 (https=) |
| SG (1) | SG11202109399SA (https=) |
| TW (1) | TW202104198A (https=) |
| WO (1) | WO2020186006A1 (https=) |
| ZA (1) | ZA202106284B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| CA3075062A1 (en) | 2017-09-11 | 2019-03-14 | Cyteir Therapeutics, Inc. | Rad51 inhibitors |
| JP7460649B2 (ja) | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１インヒビター |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| WO2020257752A1 (en) | 2019-06-21 | 2020-12-24 | Cyteir Therapeutics, Inc. | Methods of using rad51 inhibitors for treatment of pancreatic cancer |
| EP4108663A1 (en) * | 2020-02-19 | 2022-12-28 | Simcere Pharmaceutical Co., Ltd. | Substituted aryl compound |
| WO2023078271A1 (zh) * | 2021-11-02 | 2023-05-11 | 上海旭成医药科技有限公司 | 芳香化合物、其制备方法、中间体、药物组合物和应用 |
| CN118891258A (zh) * | 2022-03-29 | 2024-11-01 | 正大天晴药业集团股份有限公司 | 含有噻唑环的化合物 |
| CN114736173B (zh) * | 2022-05-24 | 2024-06-11 | 无锡捷化医药科技有限公司 | 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法 |
| EP4574817A1 (en) * | 2023-12-21 | 2025-06-25 | LoQus23 Therapeutics Limited | Inhibitory compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS6230780A (ja) | 1985-04-17 | 1987-02-09 | Ss Pharmaceut Co Ltd | １，７−ナフチリジン誘導体及びこれを含有する薬剤 |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| EP0834575B1 (en) | 1990-12-06 | 2001-11-28 | Affymetrix, Inc. (a Delaware Corporation) | Identification of nucleic acids in samples |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| CN103403002B (zh) | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
| SG11201407919WA (en) * | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
| JP2017100949A (ja) | 2014-04-01 | 2017-06-08 | 大日本住友製薬株式会社 | ５員環ヘテロアリール誘導体 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2016140971A1 (en) * | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
| US10442817B2 (en) * | 2015-06-04 | 2019-10-15 | Drexel University | Inhibitors of RAD52 recombination protein and methods using same |
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| CA3075062A1 (en) * | 2017-09-11 | 2019-03-14 | Cyteir Therapeutics, Inc. | Rad51 inhibitors |
| JP7460649B2 (ja) | 2019-03-12 | 2024-04-02 | サイティアー セラピューティクス，インコーポレイティド | Ｒａｄ５１インヒビター |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
-
2020
- 2020-03-12 JP JP2021553834A patent/JP7460649B2/ja active Active
- 2020-03-12 CN CN202080035279.0A patent/CN114072390B/zh active Active
- 2020-03-12 CA CA3132987A patent/CA3132987A1/en active Pending
- 2020-03-12 PH PH1/2021/552147A patent/PH12021552147A1/en unknown
- 2020-03-12 AU AU2020235089A patent/AU2020235089A1/en not_active Abandoned
- 2020-03-12 MX MX2021010916A patent/MX2021010916A/es unknown
- 2020-03-12 SG SG11202109399SA patent/SG11202109399SA/en unknown
- 2020-03-12 US US16/816,393 patent/US11247988B2/en active Active
- 2020-03-12 TW TW109108203A patent/TW202104198A/zh unknown
- 2020-03-12 KR KR1020217032591A patent/KR20210127790A/ko not_active Abandoned
- 2020-03-12 WO PCT/US2020/022293 patent/WO2020186006A1/en not_active Ceased
- 2020-03-12 BR BR112021017336A patent/BR112021017336A2/pt not_active Application Discontinuation
- 2020-03-12 EP EP20768883.9A patent/EP3938358B1/en active Active
- 2020-03-12 IL IL285889A patent/IL285889B2/en unknown
-
2021
- 2021-08-30 ZA ZA2021/06284A patent/ZA202106284B/en unknown
- 2021-12-16 US US17/552,577 patent/US11932636B2/en active Active
-
2024
- 2024-01-30 US US18/427,164 patent/US20240360120A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021017336A2 (pt) | 2021-11-09 |
| US20220259198A1 (en) | 2022-08-18 |
| US11247988B2 (en) | 2022-02-15 |
| IL285889B2 (en) | 2024-09-01 |
| JP7460649B2 (ja) | 2024-04-02 |
| WO2020186006A1 (en) | 2020-09-17 |
| US20240360120A1 (en) | 2024-10-31 |
| KR20210127790A (ko) | 2021-10-22 |
| ZA202106284B (en) | 2023-02-22 |
| PH12021552147A1 (en) | 2023-01-04 |
| EP3938358A1 (en) | 2022-01-19 |
| CA3132987A1 (en) | 2020-09-17 |
| SG11202109399SA (en) | 2021-09-29 |
| US11932636B2 (en) | 2024-03-19 |
| CN114072390B (zh) | 2024-06-11 |
| TW202104198A (zh) | 2021-02-01 |
| EP3938358B1 (en) | 2024-10-02 |
| AU2020235089A1 (en) | 2021-09-23 |
| IL285889A (en) | 2021-10-31 |
| IL285889B1 (en) | 2024-05-01 |
| US20200291014A1 (en) | 2020-09-17 |
| CN114072390A (zh) | 2022-02-18 |
| JP2022525069A (ja) | 2022-05-11 |
| EP3938358A4 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004221A (es) | Inhibidores de rad51. | |
| PH12021552147A1 (en) | Rad51 inhibitors | |
| MX2023000081A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| PH12021552205A1 (en) | Combinations of rad51 and parp inhibitors | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12022550892A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| ZA202006549B (en) | Pyridazinones as parp7 inhibitors | |
| PH12019501812A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
| MX2020009347A (es) | Picolinamidas como fungicidas. | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| MX2018010374A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| MX2020000367A (es) | Inhibidores de rad51. | |
| MX375499B (es) | Purificación de pleuromutilina. | |
| MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |